Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NewAmsterdam Pharma Co NVNAMS +1.05%45 PS Ratio is 482.07 as of Aug. 08, 2026, which is 327% above its 10-year median of 112.87. GuruFocus rates NAMS with a GF Score™ of 45/100 and a GF Value™ of $10.42 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 929 Biotechnology companies, NewAmsterdam Pharma Co NV ranks worse than 87.94% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, NewAmsterdam Pharma Co NV's share price is $27.96.
NewAmsterdam Pharma Co NV's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was $0.06. Hence, NewAmsterdam Pharma Co NV's PS Ratio for today is 482.07.
The historical rank and industry rank for NewAmsterdam Pharma Co NV's PS Ratio or its related term are showing as below:
NAMS'
s PS Ratio Range Over the Past 10 Years
Min: 31.18 Med: 112.87 Max: 607.93
Current: 482.07
During the past 6 years, NewAmsterdam Pharma Co NV's highest PS Ratio was 607.93. The lowest was 31.18. And the median was 112.87.
NAMS's PS Ratio is ranked worse than 87.94% of 929
companies
in the Biotechnology industry
Industry Median: 9.49
vs NAMS: 482.07
During the past 6 years, NewAmsterdam Pharma Co NV's highest 3-Year average Revenue per Share Growth Rate was -67.30% per year. The lowest was -67.30% per year. And the median was -67.30% per year.
NewAmsterdam Pharma Co NV (NAS:NAMS) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
NewAmsterdam Pharma Co NV PS Ratio Related Terms
NewAmsterdam Pharma Co NV PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, NewAmsterdam Pharma Co NV's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NewAmsterdam Pharma Co NV PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NewAmsterdam Pharma Co NV's PS Ratio distribution charts can be found below:
* The bar in red indicates where NewAmsterdam Pharma Co NV's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
NewAmsterdam Pharma Co NV's Share Price of today is $27.96. NewAmsterdam Pharma Co NV's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.06.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
NewAmsterdam Pharma Co NV (NAMS) has a PS Ratio of 482.07 as of Aug. 08, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on NewAmsterdam Pharma Co NV and its competitors. This is 327% above median its historical median of 112.87. Over the past decade, NewAmsterdam Pharma Co NV's PS Ratio has ranged from 31.18 to 607.93. According to the industry distribution chart, NewAmsterdam Pharma Co NV ranks #817 out of 929 companies in the Biotechnology industry, placing it in the top 87.9%.
Is NewAmsterdam Pharma Co NV's PS Ratio too high?
NewAmsterdam Pharma Co NV's current PS Ratio of 482.07 is 327% above median its 10-year median of 112.87. Over the past 10 years, this metric has ranged from a low of 31.18 to a high of 607.93. The Biotechnology industry median PS Ratio is 9.49. NewAmsterdam Pharma Co NV's value of 482.07 is 4979.8% above this industry median. Based on the distribution chart, NewAmsterdam Pharma Co NV ranks #817 out of 929 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, NewAmsterdam Pharma Co NV has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NewAmsterdam Pharma Co NV's PS Ratio compare to ARQT and IDYA?
According to the Biotechnology industry distribution chart, NewAmsterdam Pharma Co NV ranks #817 out of 929 companies for PS Ratio. This places NewAmsterdam Pharma Co NV in the lower half of its industry. The industry median PS Ratio is 9.49. NewAmsterdam Pharma Co NV's value of 482.07 is 4979.8% above this benchmark. Historically, NewAmsterdam Pharma Co NV's own PS Ratio has ranged from 31.18 to 607.93 over the past decade. While the company's 10-year median is 112.87 vs. the industry median of 9.49, NewAmsterdam Pharma Co NV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.49, based on 929 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NewAmsterdam Pharma Co NV's current PS Ratio of 482.07 is 4979.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on NewAmsterdam Pharma Co NV and its competitors. For the Biotechnology industry, the median PS Ratio is 9.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NewAmsterdam Pharma Co NV's current PS Ratio is 482.07, which is 327% above median its own 10-year median of 112.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NewAmsterdam Pharma Co NV stock overvalued right now?
Based on GuruFocus' analysis, NewAmsterdam Pharma Co NV (NAMS) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.42, compared to a current price of $27.96 — trading 168.3% above its estimated fair value. The current PS Ratio is 482.07, which is 327% above median its 10-year median of 112.87 and 4979.8% above the Biotechnology industry median of 9.49. NewAmsterdam Pharma Co NV's overall GF Score™ is 45/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For NewAmsterdam Pharma Co NV (NAMS), the current PS Ratio is 482.07 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NewAmsterdam Pharma Co NV (NAMS) Overvalued in 2026?
Based on GuruFocus' analysis, NewAmsterdam Pharma Co NV stock appears to be overvalued.
The current stock price of $27.96 is trading 168.3% above its estimated GF Value™ of $10.42.
GuruFocus considers NewAmsterdam Pharma Co NV to be Significantly Overvalued.
Key valuation signals for NAMS:
PS Ratio: 482.07 (327% above median its 10-year median of 112.87)
GF Value™: $10.42 vs. price of $27.96 (168.3% above fair value)
Industry Position: 4979.8% above the Biotechnology median (#817 of 929)
No single metric tells the full story. See the NAMS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
45GF Score
Get the complete analysis for NAMS
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NAMS has been successfully added to your 
